- Agreement with the U.S. government addresses prescription drug costs and encourages other wealthy nations to reward biopharmaceutical innovation
- Influenza portfolio to be made available through TrumpRx.gov and through Genentech’s recently-launched direct-to-patient program
- Company commitment to U.S. manufacturing, infrastructure, and R&D reaffirmed, building on the recent $50 billion investment announcement and recent groundbreaking of new manufacturing facility in North Carolina
- Government exempts Genentech portfolio from tariffs, enabling Genentech’s continued investment and expansion of its manufacturing footprint in the U.S.
Category Archives: AZBio News
GSK enters agreement with U.S. government to lower drug prices and expand access to respiratory medicines for millions of Americans
- Voluntary agreement delivers on all four of President Trump’s requests and reduces the cost of medicines for Americans
- Includes products used to treat the more than 40 million patients in the U.S. who suffer from respiratory conditions such as asthma and COPD
- Builds on GSK’s decades-long commitment to make products accessible worldwide to those who need them
Amgen Takes Action with the U.S. Government to Lower the Cost of Medicines for American Patients
Underscores Long-Standing Commitment to Investing in Innovation and U.S. ManufacturingContinue reading
Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans Eliquis® (apixaban), the Nation’s #1 Prescribed Oral Blood Thinner, Soon Available for Free to Medicaid Program
Agreement Provides Tariff Relief for a 3-Year PeriodContinue reading
Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
- Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
- Enlicitide has potential to be first approved oral PCSK9 inhibitor designed to help meet critical unmet needs for patients and will be offered at an affordable price to eligible Americans through a direct-to-patient program
- Merck has committed more than $70 billion in U.S. investments to boost domestic production and innovation
Novartis and US government reach agreement on lowering drug prices in the US
Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricing
Additional Novartis medicines will be made available through direct-to-patient platforms in 2026
Company remains committed to investing in markets that value innovation and implement policies that support broad and fast access to medicines
Picard Medical Marks Public Company Milestone by Ringing the NYSE Opening Bell
Picard Medical, Inc. / SynCardia Systems LLC commemorate the Company’s transition to the public markets and continued advancement of their Total Artificial Heart technologyContinue reading
Phoenix Children’s Research Institute Secures Three Prestigious National Institutes of Health (NIH) Grants
Phoenix Children’s Research Institute at the University of Arizona College of Medicine – Phoenix has been awarded three new R01 grants from the National Institutes of Health (NIH), the gold standard of federally funded research awards.Grant funding will advance pediatric lung and spine research.Continue reading
Secretary Kennedy Adds Duchenne Muscular Dystrophy, Metachromatic Leukodystrophy to Newborn Screenings
WASHINGTON—DECEMBER 16, 2025 — The U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. today approved the addition of Duchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD) to the Recommended Uniform Screening Panel (RUSP) following scientific review and public comment. Early detection of both conditions allows children to receive FDA-approved therapies at the most effective time, helping to slow disease progression and preserve their quality of life.
NuvOx Announces First Patient in Phase IIb Stroke Trial
Tucson, AZ –December 15, 2025, NuvOx Therapeutics, Inc. (“NuvOx”) announced that the first patient has been enrolled in the Phase IIb NOVEL trial (NanO2 in Large Vessel Occlusion Stroke (NOVEL): a multicenter single-blind, randomized, placebo-controlled biomarker end point clinical trial of perfluorocarbon in acute ischemic stroke due to large vessel occlusion (LVO).
The NOVEL trial is funded by the Efficacy and Mechanism Evaluation (EME) Program, a partnership between the National Institute for Health Care Research (NIHR) and the Medical Research Council (MRC). The trial is also co-sponsored by the University of Glasgow and NHS Greater Glasgow and Clyde.Continue reading